Clinical Trials Browser

Phase 2 × pegfilgrastim × Sarcoma × Clear all

NCT01871766 2025-12-17

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 2 Active not recruiting

Rhabdomyosarcoma

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Phase 2 Recruiting

Rhabdomyosarcoma

NCT02531308 2022-09-28

DLBCL

Phase 2 Terminated

5 enrolled 5 charts

LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT01313884 2017-11-24

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Phase 2 Terminated

3 enrolled 7 charts

Bone Neoplasms, Sarcoma, Ewing

NCT00003955 2014-02-14

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Phase 2 Completed

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT00101127 2014-02-14

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

Phase 2 Completed

Sarcoma

NCT00073983 2012-03-12

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Phase 2 Completed

54 enrolled 8 charts

Chondrosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT00035620 2010-02-26

Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

Phase 2 Completed

Bone Neoplasms, Neutropenia, Sarcoma